

Treadwell Announces the Formation and Members of Scientific Advisory Board

Description

TORONTO & SAN FRANCISCO (BUSINESS WIRE) Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet needs in cancer, today announced the formation of a Scientific Advisory Board comprised of prominent oncology leaders and drug developers. The SAB will work closely with Treadwell to advance the company's pipeline of small molecules, biologics and cell therapies.

"We are delighted and honored to be working with this prestigious group of innovators and thought leaders as our Scientific Advisory Board. We are very much looking forward to collaborating with this group to inform and shape our research and development efforts in advancing our pipeline," said Roger Sidhu, M.D., Acting CEO of Treadwell. "This SAB brings tremendous experience in advancing novel therapeutics in oncology from early to late stage development including drug approvals. We are confident that this group will be invaluable in supporting the development of our pipeline with a focus on our lead program CFI-400945, a PLK4 inhibitor currently being advanced in AML."

The founding members of the Treadwell Scientific Advisory Board are:

Antoni Ribas, M.D., Ph.D., is currently Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center and director of the Parker Institute for Cancer Immunotherapy at UCLA. Dr. Ribas has played a pivotal role in the development and approval pembrolizumab in advanced melanoma and multiple additional drugs in this disease. Dr. Ribas was formerly President of the American Association for Cancer Research and has been elected to the National Academy of Medicine.

Carl June, M.D., is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania and director of Center for Cellular Immunotherapies at the University of Pennsylvania. Dr. June is internationally recognized for his role in pioneering CAR-T cell therapy which led to the first FDA-approved cellular therapy for children and young adults with acute lymphoblastic leukemia. Dr. June has published more than 500 manuscripts and is the recipient of multiple prestigious scientific achievement awards and is a member of the National Academy of Medicine and the National Academy of Sciences.

Pasi A. Jänne, M.D., Ph.D., is a world renowned translational medical oncologist and the Senior Vice President of Translational Medicine at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He is the Director of the Belfer Center for Applied Cancer Science. He was a co-discoverer of epidermal growth factor receptor (EGFR) mutations that has led to the development of multiple therapeutic strategies for patients with EGFR mutant lung cancer. Dr. Jänne has received the 2024 Medal of Honor from the American Cancer Society and multiple awards from ASCO, AACR and ESMO.

S. Gail Eckhardt is Associate Dean of Experimental Therapeutics at Baylor College of Medicine and Associate Director of Translational Research at the Dan L Duncan Comprehensive Cancer Center. Dr.

Eckhardt has served on numerous committees and study sections, including the ASCO Molecular Oncology Task Force, the ASCO Board of Directors, the FDA Oncology Drugs Advisory Committee, and the National Cancer Institute (NCI) Cancer Centers Study Section. She serves on 10 external advisory boards of NCI-designated cancer centers, is a past member of the Board of Directors of the Association of American Cancer Institutes (AACI) and previous Chair of the Cancer Prevention and Research Institute of Texasâ?? (CPRIT) Clinical Trials Advisory Committee. She is a current member of the National Academies of Science, Engineering, and Medicineâ??s Cancer Policy Forum. Dr. Eckhardt serves on the Board of Directors of Syros Pharmaceuticals and Exelixis and the Scientific Advisory Board of Amgen.

Lillian L Siu, M.D., FRCPC, is an internationally recognized expert in the development of novel cancer therapeutics. Dr. Siu is a senior medical oncologist at the Princess Margaret Cancer Centre and a Professor of Medicine at the University of Toronto. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at the Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). Internationally, Dr. Siu was the recipient of the US NCI Michael C. Christian Award in Oncology Drug Development in 2010. She was awarded the TAT 2020 Honorary Award for contributions in the development of anticancer drugs. In 2023, Dr. Siu is currently the co-Editor-in-Chief for AACRâ??s newest journal *Cancer Research Communications* and is on the editorial board for *Cell and Cancer Cell*.

Patricia LoRusso, has been a practicing academic medical oncologist performing clinical/translational research in early phase clinical trials for over 30 years, and is currently the Associate Director of Experimental Therapeutics at the Yale Cancer Center and director of their Early Phase Clinical Trials Program. She has had continuous NIH/NCI peer review funding for over 28 years, as well as numerous other team science grants, including SPOR funding and other funding mechanisms such as Stand Up to Cancer (Co-Leader: Melanoma Dream Team), the Department of Defense (DOD) and the Komen Foundation (Co-leader, KG111063: Targeting Stem Cells in Triple-Negative Breast Cancer (TNBC) in Different Racial Populations). In addition to serving in NCI extramural positions, Dr. LoRusso is currently serving a 3-year term as the chair of their New Agents Committee (NAC), committees for the Cancer Research United Kingdom (CRUK). Dr. LoRusso has also served in leadership positions of several other organizations, including the Board of Directors and current President-elect of the AACR, and education and scientific committees of the ASCO. Internationally, she has taught several clinical trials educational workshops, educating many physicians and scientists across the globe. Working closely over the past 3 decades with patients suffering from advanced malignancies, Dr. LoRusso has become an advocate, not only for cancer researchers and clinicians, but more importantly for the patients and their caregivers.

Tak Wah Mak, Ph.D., co-founder of Treadwell Therapeutics, is one of the worldâ??s most cited and accomplished scientists. Dr. Mak is currently a Senior Scientist at Princess Margaret Cancer Centre, Director of the Campbell Family Institute for Breast Cancer Research and Professor, Department of Medical Biophysics at the University of Toronto. Dr. Mak is credited with the discovery of the T-cell receptor and pioneering work in the genetics of immunology, including publishing a landmark paper on the discovery and function of the immune checkpoint protein CTLA-4. Dr. Mak is also the founder of Agios Pharmaceuticals, whose lead compound, IDHIFAÂ®, was approved by the FDA for acute myelogenous leukemia in 2017. Dr. Mak has served as author on over 1000 peer-reviewed articles. Dr. Mak is a Fellow of the AACR Academy, has received honorary degrees from many universities around the world and has received various international awards such as the Paul Ehrlich Prize, the Ludwig Darmstaeder Prize and most recently the 2023 International Award for Extraordinary Achievement in Cancer Research from the Pezcoller Foundation and the American Association for Cancer Research

(AACR).

About Treadwell Therapeutics

Treadwell Therapeutics is a clinical-stage oncology company developing novel medicines to address unmet needs in patients with cancer. The Company's robust, internally developed clinical pipeline includes CFI-400945 (PLK4 inhibitor), CFI-402257 (TTK/Mps1 inhibitor) and CFI-402411 (HPK1 inhibitor). Treadwell also has a broad pre-clinical pipeline with multiple biologic and next generation TCR based autologous cell therapy programs. For more information, please visit www.treadwelltx.com.

Contact

ir@treadwelltx.com

Date Created

February 14, 2024